Cell And Gene Therapy Logistics Management: A Holistic Approach

By Natalie Sacarakis, Head, Cell and Gene Therapy Logistics, IQVIA CAGT Center of Excellence

Cell and gene therapy (CAGT) clinical trial operations exhibit defining characteristics such as intricate protocols, the management of expensive and irreplaceable assets, and accelerated timelines. Furthermore, autologous and allogeneic cell therapies, as well as in vivo and ex vivo gene therapies and gene editing, each have distinct logistics needs.

These aspects necessitate clinical operations teams to meticulously plan, oversee, and provide training for supply chain logistics. Given the interconnectedness of the manufacturing process, asset shipping, site handling, and the patient journey, it becomes imperative to adopt a comprehensive logistics management strategy that considers these factors right from the outset and goes beyond mere asset tracking.

Employing a holistic approach to logistics management also plays a crucial role in supporting sites by enhancing risk management and compliance measures. Learn how to recognize essential logistics requirements to create an all-encompassing and comprehensive approach to logistics management that successfully addresses the spectrum of complexity across all CAGT assets by accessing the full white paper.